Refine
Year of publication
Document Type
- Article (20)
- Conference Proceeding (1)
- Preprint (1)
Language
- English (22)
Has Fulltext
- yes (22)
Is part of the Bibliography
- no (22)
Keywords
- nivolumab (2)
- radiotherapy (2)
- temozolomide (2)
- 140Ce (1)
- AVM hemorrhage (1)
- Angiography (1)
- Antiplatelet therapy (1)
- Atomic and Molecular Physics (1)
- Cancer genomics (1)
- Cerebral vasospasm (1)
- Coincidence measurement (1)
- DBS (1)
- Death rates (1)
- Deep brain stimulation (1)
- Diagnostic medicine (1)
- FFPE (1)
- Glioblastoma (1)
- Hardware erosion (1)
- Hemorrhage (1)
- Impulse generator (1)
- Long non-coding RNAs (1)
- MGMT (1)
- MGMT promoter (1)
- Magnetic resonance imaging (1)
- Multivariate analysis (1)
- NKG2D (1)
- Neuroimaging (1)
- Nuclear resonance fluorescence (1)
- Obesity (1)
- PD-L1 (1)
- Parkinson’s disease (1)
- Proteomics (1)
- Pygmy Dipole Resonance (1)
- Quasi-particle phonon model (1)
- SWATH (1)
- Scalp defect (1)
- Subarachnoid hemorrhage (1)
- Temozolomide (1)
- Tissue expander (1)
- Transcriptomics (1)
- VIM (1)
- adult (1)
- biomarker (1)
- brain shift (1)
- cerebrospinal fluid (1)
- chemotherapy (1)
- clinical trial (1)
- essential tremor (1)
- glioblastoma (1)
- glioma (1)
- immune escape (1)
- magnetic resonance imaging (1)
- medulloblastoma (1)
- miRNA (1)
- newly diagnosed glioblastoma (1)
- pressure cycling technology (1)
- proteome (1)
- randomized (1)
- subgrouping (1)
- targeted therapy (1)
- tumor (1)
- unmethylated MGMT (1)
- ventralis intermedius nucleus (1)
- γ-ray spectroscopy (1)
Institute
- Medizin (17)
- Physik (3)
- Geowissenschaften (2)
- ELEMENTS (1)
- Frankfurt Institute for Advanced Studies (FIAS) (1)
- Sportwissenschaften (1)
Malignant gliomas are intrinsic brain tumors with a dismal prognosis. They are well-adapted to hypoxic conditions and poorly immunogenic. NKG2D is one of the major activating receptors of natural killer (NK) cells and binds to several ligands (NKG2DL).
Here we evaluated the impact of miRNA on the expression of NKG2DL in glioma cells including stem-like glioma cells. Three of the candidate miRNA predicted to target NKG2DL were expressed in various glioma cell lines as well as in glioblastomas in vivo: miR-20a, miR-93 and miR-106b. LNA inhibitor-mediated miRNA silencing up-regulated cell surface NKG2DL expression, which translated into increased susceptibility to NK cell-mediated lysis. This effect was reversed by neutralizing NKG2D antibodies, confirming that enhanced lysis upon miRNA silencing was mediated through the NKG2D system. Hypoxia, a hallmark of glioblastomas in vivo, down-regulated the expression of NKG2DL on glioma cells, associated with reduced susceptibility to NK cell-mediated lysis. This process, however, was not mediated through any of the examined miRNA. Accordingly, both hypoxia and the expression of miRNA targeting NKG2DL may contribute to the immune evasion of glioma cells at the level of the NKG2D recognition pathway. Targeting miRNA may therefore represent a novel approach to increase the immunogenicity of glioblastoma.
Purpose: The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastoma patients comparing temozolomide (TMZ) to lomustine/TMZ, and GLARIUS (n = 170) for MGMT unmethylated glioblastoma patients comparing TMZ to bevacizumab/irinotecan, both in addition to surgery and radiotherapy.
Methods: The impact of obesity (BMI ≥ 30 kg/m2) on overall survival (OS) and progression-free survival (PFS) was investigated with Kaplan–Meier analysis and log-rank tests. A multivariable Cox regression analysis was performed including known prognostic factors as covariables.
Results: Overall, 22.6% of patients (67 of 297) were obese. Obesity was associated with shorter survival in patients with MGMT methylated glioblastoma (median OS 22.9 (95% CI 17.7–30.8) vs. 43.2 (32.5–54.4) months for obese and non-obese patients respectively, p = 0.001), but not in MGMT unmethylated glioblastoma (median OS 17.1 (15.8–18.9) vs 17.6 (14.7–20.8) months, p = 0.26). The prognostic impact of obesity in MGMT methylated glioblastoma was confirmed in a multivariable Cox regression (adjusted odds ratio: 2.57 (95% CI 1.53–4.31), p < 0.001) adjusted for age, sex, extent of resection, baseline steroids, Karnofsky performance score, and treatment arm.
Conclusion: Obesity was associated with shorter survival in MGMT methylated, but not in MGMT unmethylated glioblastoma patients.